P2X Receptor Modulators

Product #

Description

Biochem/physiol Actions

Add to Cart

A9736 A-438079 hydrochloride hydrate ≥98% (HPLC) A-438079 hydrochloride hydrate is a selective P2X7 purinoceptor antagonist in both human and rat with minimal activity at 75 different G-protein-coupled receptors, enzymes, transporters, and ion channels tested.
A2979 A-317491 sodium salt hydrate ≥98% (HPLC), powder Novel P2X3 and P2X2/3 receptor antagonist
A1612 AF-353 hydrochloride ≥98% (HPLC), powder AF-353 is a potent antagonist of P2X3 homotrimers and P2X2/3 heterotrimers with a pIC50 range of 7.3 - 8.5. The compound does not affect other P2X family members at 300-fold excess concentrations. AF-353 significantly reversed pain behavior in a rat model of bone cancer pain.
A7231 AZ11645373 ≥98% (HPLC), solid AZ11645373 is a selective and potent human P2X7 purinoceptor antagonist. KB values range from 5-20 nM for human P2X7 receptor inhibition. It is 500-fold less effective ats an inhibitor of rat P2X7 receptor responses.
B3756 8-Bromoadenosine 5′-triphosphate sodium salt ≥90% (HPLC) P2X purinoceptor agonist similar in reactivity to ATP.
SML1701 BX430 ≥98% (HPLC) BX430 is a selective noncompetitive allosteric antagonist of human P2X4 receptor channels. P2X4 receptors are highly expressed in the CNS, and have been studied as a therapeutic target for neuropathic pain and inflammation, and treatment of traumatic brain injury, cerebral ischemia, and spinal cord injury. BX430 is highly selective for human P2X4, with minimal activity towards other P2X subtypes, including P2X1–P2X3, P2X5, and P2X7. BX430 is also an antagonist of zebrafish P2X4 but has no effect on rat and mouse P2X4 receptors. BX430 has an IC50 value of 540 nM.
C1506 Cytidine 5′-triphosphate disodium salt ≥95% P2X4 purinergic receptor agonist.
C9274 Cytidine 5′-triphosphate disodium salt ~95% P2X4 purinergic receptor agonist.
SML1708 JNJ-47965567 ≥98% (HPLC) JNJ-47965567 is a potent P2X7 antagonist with high affinity for the rat receptor (pKi = 8.7). It is centrally available after systemic injection with a superior brain:plasma distribution compared to other available P2X7 antagonists. JNJ-47965567 was shown to suppress epileptic seizures in a mouse model of epilepsy. It appears to have a disease modifying effect since spontaneous seizure rates did not increase once treatment with JNJ-477965567 was stopped.
M6517 α,β-Methyleneadenosine 5′-triphosphate lithium salt ≥93% (HPLC), solid P2 purinoceptor agonist that is more potent than ATP at the P2X subtype.
M7510 β,γ-Methyleneadenosine 5′-triphosphate disodium salt ≥95%, solid Selective P2X purinoceptor agonist that is more potent than ATP, but less potent than α, β-methylene-L-adenosine 5′-triphosphate.
M152 2-(Methylthio)adenosine 5′-diphosphate trisodium salt hydrate ≥89% (HPLC), solid 2-Methylthio-ADP (2-ME-SADP) is a P2 purinoceptor agonist, which induces platelet aggregation and shape change and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1. Compared with ADP, 2-methylthio-ADP was 3-5 times as active as an aggregating agent and 150-200 times as active as an inhibitor of cyclic AMP accumulation. Purinergic signaling may be an important factor in TSP-1-mediated cell-matrix and cell-cell interactions such as those occurring during development and repair.
M7684 MRS 2159 >98% (HPLC), solid P2X1 purinoceptor antagonist.
N8652 NF 023 hydrate ≥98% (HPLC), solid NF 023 is a potent, selective P2X1 purinoceptor antagonist.
SML0753 PSB-12062 ≥98% (HPLC) PSB-12062 is a P2X4 receptor antagonist. P2X4 receptors are highly expressed in the CNS, and have been studied as a therapeutic target for neutopathic pain, and treatment of traumatic brain injury, cerebral ischemia, and spinal cord injury. PBS-12062 is a new P2X4-specific antagonist with equal potency against human, rat and mouse receptors (IC50s 1.38, 0.92 and 1.76 μM, respecitively). The compound does not display significant inhibition of human P2X1, P2X2, P2X3 or P2X7 at 10 μM.
P178 Pyridoxal phosphate-6-azo(benzene-2,4-disulfonic acid) tetrasodium salt hydrate solid, ≥98% (HPLC) Non-selective P2 purinoceptor antagonist which blocks responses at both pre- and post-junctional sites.
SML0740 TNP-ATP sodium salt 10 mM in phosphate buffer, ≥90% (HPLC) TNP-ATP phosphate buffered solution is a stable, aqueous buffered solution of TNP-ATP, a purinoceptor P2X2/3 antagonist.